To gain insight into the mechanism of cell death induced by p53 reactivation in SCLC, we treated Type D cells with pharmacological inhibitors of apoptosis (ZVAD-FMK), ferroptosis (Ferrostatin-1), necropstosis (Necrostatin-1s), and cyclophilin-dependent death (Cyclosporin A). This evidence concerns the gene TP53 and small cell lung carcinoma.